TWi completes Phase IIb study of AC-201
AC-201 is an orally available small molecule in development which modulates the intracellular synthesis of the cytokine IL-1Beta. TWi Pharmaceuticals acting president Calvin Chih-Kuang Chen said, "We are
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have refused cisplatin-based chemotherapy.